VIDEO: Definition of EGFR-mutated lung cancer continues to expand

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Yeah, so the EGFR mutation lung cancer field has really expanded. We usually think about EGFR as the classical mutation, deletion 19 and 858R mutation. But in the last, I will say, five to 10 years, we discovered that other kinase domain mutations, such as exon 20 insertion or EGFR PACC mutation, P-A-C-C mutations. also give the same oncogenesis drive lung cancer growth. Those are not uncommon with NGS testing. For example, exon 20 is around 10% of all EGFR. PACC mutation is around the 12% of all EGFR. So there are newer drug development specifically aiming for those space, including exon 20.

We have amivantamab approved in combination with chemo in the front-line setting, and a number of targeted therapy of FDA Breakthrough designation. PACC mutation will also start to see TKI that's giving really good front-line benefit for this patient population. So I will have to say that EGFR research not only become deeper, meaning that we have different mechanism of action, different newer drugs, we also become wider, so covering all spectrum of EGFR mutation, which is definitely a great thing for patients. Our goal, to me, as a provider, really is hoping to be able to provide something for any patients who have whatever atypical/typical mutation at any junction of their treatment. It can be front-line. It can be second-line. It can be early stage. I think we're getting there slowly.